BACKGROUND: Sarcopenia or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. This study aimed to examine the impact of sarcopenia on surgical complications and survival outcomes in patients with endometrial cancer. METHODS: A retrospective review of endometrial cancer patients who underwent surgery between 2005 and 2009 was performed. Sarcopenia was assessed on preoperative computed tomography (CT) scan by measurement of the lumbar psoas muscle cross-sectional area and defined as any value below the median (<4.33 cm(2)). Sarcopenic obesity was defined as sarcopenia plus a body mass index (BMI) of 30 kg/m(2) or higher. Microsatellite instability (MSI) was analyzed using the National Cancer Institute (NCI) consensus markers and tumor from hysterectomy specimens. RESULTS: Of 122 patients, 27 (22%) met the criteria for sarcopenic obesity. Sarcopenic patients were older than patients with normal muscle mass (mean age, 69.7 vs. 62.1 years; p < 0.001), had a lower BMI (31.1 vs. 39.4 kg/m(2); p < 0.001), and had more comorbidities (p = 0.048). Sarcopenia was not associated with tumor MSI, hospital stay, 90-day readmission rate, or early/late complications. Patients with sarcopenia had a shorter recurrence-free survival than nonsarcopenic patients (median 23.5 vs. 32.1 months; log-rank p = 0.02), but did not differ in terms of overall survival (log-rank p = 0.25). After adjustment for race, BMI, lymphocyte count, and tumor histology, sarcopenia was associated with a fourfold shorter recurrence-free survival (adjusted hazard ratio [HRadj], 3.99; 95% confidence interval [CI], 1.42-11.3). CONCLUSIONS: Sarcopenia has an impact on recurrence-free survival, but does not appear to have a negative impact on surgical outcomes or overall survival among endometrial cancer patients who undergo preoperative CT scan.
BACKGROUND:Sarcopenia or loss of skeletal muscle mass is an objective measure of frailty associated with functional impairment and disability. This study aimed to examine the impact of sarcopenia on surgical complications and survival outcomes in patients with endometrial cancer. METHODS: A retrospective review of endometrial cancerpatients who underwent surgery between 2005 and 2009 was performed. Sarcopenia was assessed on preoperative computed tomography (CT) scan by measurement of the lumbar psoas muscle cross-sectional area and defined as any value below the median (<4.33 cm(2)). Sarcopenic obesity was defined as sarcopenia plus a body mass index (BMI) of 30 kg/m(2) or higher. Microsatellite instability (MSI) was analyzed using the National Cancer Institute (NCI) consensus markers and tumor from hysterectomy specimens. RESULTS: Of 122 patients, 27 (22%) met the criteria for sarcopenic obesity. Sarcopenic patients were older than patients with normal muscle mass (mean age, 69.7 vs. 62.1 years; p < 0.001), had a lower BMI (31.1 vs. 39.4 kg/m(2); p < 0.001), and had more comorbidities (p = 0.048). Sarcopenia was not associated with tumor MSI, hospital stay, 90-day readmission rate, or early/late complications. Patients with sarcopenia had a shorter recurrence-free survival than nonsarcopenic patients (median 23.5 vs. 32.1 months; log-rank p = 0.02), but did not differ in terms of overall survival (log-rank p = 0.25). After adjustment for race, BMI, lymphocyte count, and tumor histology, sarcopenia was associated with a fourfold shorter recurrence-free survival (adjusted hazard ratio [HRadj], 3.99; 95% confidence interval [CI], 1.42-11.3). CONCLUSIONS:Sarcopenia has an impact on recurrence-free survival, but does not appear to have a negative impact on surgical outcomes or overall survival among endometrial cancerpatients who undergo preoperative CT scan.
Authors: J I Risinger; K Hayes; G L Maxwell; M E Carney; R K Dodge; J C Barrett; A Berchuck Journal: Clin Cancer Res Date: 1998-12 Impact factor: 12.531
Authors: R N Baumgartner; K M Koehler; D Gallagher; L Romero; S B Heymsfield; R R Ross; P J Garry; R D Lindeman Journal: Am J Epidemiol Date: 1998-04-15 Impact factor: 4.897
Authors: Cristina Bilbao; Germán Rodríguez; Raquel Ramírez; Orlando Falcón; Laureano León; Ricardo Chirino; Juan F Rivero; Orlando Falcón; B Nicolás Díaz-Chico; Juan C Díaz-Chico; Manuel Perucho Journal: Int J Cancer Date: 2006-08-01 Impact factor: 7.396
Authors: Claude Pichard; Ursula G Kyle; Alfredo Morabia; Arnaud Perrier; Bernard Vermeulen; Pierre Unger Journal: Am J Clin Nutr Date: 2004-04 Impact factor: 7.045
Authors: Paul E Wischmeyer; Zudin Puthucheary; Iñigo San Millán; Daniel Butz; Michael P W Grocott Journal: Curr Opin Crit Care Date: 2017-08 Impact factor: 3.687
Authors: Hamed Ahmadi; James E Montie; Alon Z Weizer; Todd Morgan; Jeffrey S Montgomery; Cheryl T Lee Journal: Curr Urol Rep Date: 2015-11 Impact factor: 3.092
Authors: Jessica S Gorzelitz; Stefanie Stoller; Erin Costanzo; Ronald Gangnon; Kelli Koltyn; Amy Trentham Dietz; Ryan J Spencer; Joanne Rash; Lisa Cadmus-Bertram Journal: Support Care Cancer Date: 2021-07-25 Impact factor: 3.359
Authors: Iris J G Rutten; David P J van Dijk; Roy F P M Kruitwagen; Regina G H Beets-Tan; Steven W M Olde Damink; Toon van Gorp Journal: J Cachexia Sarcopenia Muscle Date: 2016-03-07 Impact factor: 12.910